Clinical Trials Sponsored by BonusBio Group Ltd

Total 871 results

BonusBio Group Ltd

Recruiting

Filling Bone Defects/Voids With Autologous BonoFill-II for Maxillofacial Bone Regeneration

Bone Augmentation | Bone Grafts

Israel
BonusBio Group Ltd

Completed

Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19

Covid19

Israel
BonusBio Group Ltd

Not yet recruiting

A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

ARDS
BonusBio Group Ltd

Recruiting

Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II

Bone Fracture

Israel
BonusBio Group Ltd

Completed

Filling Bone Defects/Voids With Autologous BonoFill For Maxillofacial Bone Regeneration

Bone Void in the Maxillofacial Area

Israel
Nuvo-Group, Ltd.

Completed

Evaluating the Safety of PregSense™ and Compare Its Performance to CTG in Prenatal Monitoring of Pregnant Subjects

Pregnancy

United States, Israel, Germany
Eyoto Group Ltd

Completed

A Comparison of the Diagnostic Confidence and Image Quality Between the Eyoto Theia (RDSL) and a Predicate Device.

Cataract

United States
Nuvo-Group, Ltd.

Completed

Comparative Performance of INVU™ Versus Intrauterine Pressure Catheter (IUPC) in Uterine Contractions Monitoring of Pregnant Women.

Healthy, Pregnant Women

United States
Luye Pharma Group Ltd.

Not yet recruiting

To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

Major Depressive Disorder
Luye Pharma Group Ltd.

Not yet recruiting

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017

Negative Symptoms of Schizophrenia | Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis | Hallucinations and Delusions Associated With Parkinson Disease Psychosis

China
Luye Pharma Group Ltd.

Recruiting

First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.

Advanced Solid Tumor

China
Cellular Biomedicine Group Ltd.

Not yet recruiting

Allogenic Adipose-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis

Knee Osteoarthritis

China
Luye Pharma Group Ltd.

Recruiting

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Generalized Anxiety Disorder

China
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Luye Pharma Group Ltd.

Recruiting

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Luye Pharma Group Ltd.

Enrolling by invitation

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Lianyungang Kanion Group, Ltd.

Completed

JINZHEN for Treatment of Mild to Moderate COVID-19

COVID-19

United States
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD

Parkinson Disease

China
Luye Pharma Group Ltd.

Completed

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Breast Cancer

China
Luye Pharma Group Ltd.

Completed

Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors

Advanced Solid Tumor

China
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Luye Pharma Group Ltd.

Completed

A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients

Parkinson Disease

China
Luye Pharma Group Ltd.

Completed

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Parkinson Disease

United States
Luye Pharma Group Ltd.

Completed

A Relative Bioavailability Food Effect Study of LY03005

Major Depressive Disorder

United States
Luye Pharma Group Ltd.

Completed

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

Cancer of Prostate

United States
Luye Pharma Group Ltd.

Completed

A Study of LY03005 vs Pristiq

Major Depressive Disorder

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

Parkinson Disease

United States
Luye Pharma Group Ltd.

Unknown

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Recurrent

China
Luye Pharma Group Ltd.

Completed

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

Lipid Metabolism Disorder

United States
Luye Pharma Group Ltd.

Completed

Safety, Tolerability and Pharmacokinetics Study of LY03005 (LY03005SAD)

Major Depressive Disorder

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder (LY03004SAD)

Schizophrenia | Schizoaffective Disorder

United States
Luye Pharma Group Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Luye Pharma Group Ltd.

Not yet recruiting

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Prostate Cancer

China
Luye Pharma Group Ltd.

Active, not recruiting

Comparative Efficacy, Safety, PK, and Immunogenicity Study

Osteoporosis, Postmenopausal

Poland, United States, Czechia, Bulgaria, Japan
Luye Pharma Group Ltd.

Completed

Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer

Small Cell Lung Cancer

China
Botanee Group Co., Ltd.

Completed

A Clinical Study on the Improvement of Skin and Living Conditions After Drinking Rosa Roxburghii and Pomegranate Drinks

Skin Laxity

China
Luye Pharma Group Ltd.

Completed

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

Tardive Dyskinesia | Huntington Disease

China
Botanee Group Co., Ltd.

Active, not recruiting

A 28-day Clinical Study on Facial Skin Rejuvenation

Skin Manifestations | Wrinkle | Skin | Skin Laxity

China
Luye Pharma Group Ltd.

Completed

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
Luye Pharma Group Ltd.

Completed

A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects

Healthy

China
Luye Pharma Group Ltd.

Completed

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Luye Pharma Group Ltd.

Completed

An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects

Healthy

China
Luye Pharma Group Ltd.

Enrolling by invitation

to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

Parkinson's Disease

Australia
Luye Pharma Group Ltd.

Completed

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

Parkinson Disease

United States
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003

Parkinson Disease
Luye Pharma Group Ltd.

Completed

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

Schizophrenia | Schizoaffective Disorder | Schizo Affective Disorder

United States
Kendall Healthcare Group, Ltd.

Unknown

IAL vs PS for Anterior Shoulder Dislocations

Shoulder Dislocation

United States
Luye Pharma Group Ltd.

Completed

Pilot BA Study of New LY03005 vs Pristiq

Major Depression

United States
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Parkinson's Disease

United States
Luye Pharma Group Ltd.

Completed

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

Major Depressive Disorder, Recurrent, Unspecified

United States

3

Subscribe